[ad_1]
The World Health Organization (WHO) has said it needs “more than a press release” on the Oxford / AstraZeneca vaccine to evaluate the results of the trial.
Speaking at a WHO press conference on Friday, its director of immunizations, Dr. Katherine O’Brien, said: “What we have seen is a press release.
“And what’s really the next most important step is that the data needs to be evaluated based on more than a press release.”
The Oxford / AstraZeneca published a press release on Monday
The Oxford / AstraZeneca vaccine was revealed on monday have an efficacy of up to 90% when a half dose was administered, followed by a full one.
Dr. O’Brien added: “First of all, there is only a limited amount that can be said in a press release.
“And second, it really needs to be reviewed in terms of the data and the questions about the data that may come up in the course of the review.
“It is difficult to comment on this.
“I think what we can emphasize is that from what we understand about the press release, there is certainly something interesting that has been observed.
“But there are many reasons that could underlie the differences that were observed.
“And certainly more information is needed and that includes evaluations of the immune response in the trial as well.
“So I think it’s too early for us to say anything about what we do with the data.
“And what is needed next, what we really need to see, is more than just a press release and really looking at the data and having the opportunity to ask the questions that are needed.”
:: Subscribe to the daily podcast on Apple Podcasts, Google Podcasts, Spotify, Spreaker
Was revealed early friday that the UK regulator had been asked to evaluate the inoculation developed at Oxford.
The UK government has ordered 100 million doses of the jab.
The discovery that half a dose followed by a full dose is so effective was an accident, according to AstraZeneca CEO Pascal Soriot.
Administration of two full doses of the vaccine was shown to be 62% effective. When the two different trials were averaged, the efficacy was 70%.
